Eindhoven Venture Capital Fund II (EVCF II) invested in CytoSMART Technologies, based in Eindhoven, in 2019 to fund the company’s product development and scale up ambitions. Since then, the company has grown to over 50 employees and successfully launched a number of new innovative products into the life sciences tools market. We are pleased to announce that on March 21 2022, Axion BioSystems, a US-based leading life sciences tools company focused on advanced live-cell assay systems, has acquired CytoSMART Technologies. Both companies see large synergies to accelerate further growth together.

“With Axion’s resources and experience, we look forward to accelerating our market growth and product innovation” says Joffry Maltha, CEO of CytoSMART Technologies.

We like to thank Joffry Maltha en Jan-Willem van Bree for the pleasant cooperation in the past years and wish the all the best in this new phase!

For more information, please visit the website of CytoSMART Technologies.